Table 1.
Baseline Characteristics of Perianal Crohn’s Disease (PCD) Patients Treated by Non-Biological Medications or Infliximab
| Clinical Characteristics | Patients with Non-Biological Therapy After PSI (n=64) | Patients with IFX Therapy After PSI (n=66) | P value |
|---|---|---|---|
| Gender (male) (%) | 53(82.8) | 58(87.9) | 0.414 |
| Age(y) | 27.9(17–49) | 24(17–45) | 0.345 |
| Smoking history(%) | 17(26.6) | 18(12.1) | 0.927 |
| Disease location(%) | 0.301 | ||
| L1 | 13(20.3) | 10(15.2) | |
| L2 | 22(34.3) | 23(34.8) | |
| L3 | 18(28.1) | 27(40.9) | |
| L4 | 11(17.2) | 6(9.1) | |
| Perianal only | 3(4.7) | 4(6) | 0.729 |
| Disease phenotype(%) | 0.095 | ||
| B1 | 23(35.9) | 28(42.4) | |
| B2 | 35(54.7) | 25(37.9) | |
| B3 | 6(9.4) | 13(19.7) | |
| Proctitis(%) | 35(54.7) | 41(62.1) | 0.496 |
| Interval between surgery and medication administration(d) | 34(21–48) | 33(14–50) | 0.367 |
| Prior anti-TNF exposure(%) | 3(4.7) | 7(10.6) | 0.205 |
| Complex fistula(%) | 41(64.1) | 40(60.6) | 0.684 |
| Recto-vaginal fistula(%) | 4(6.3) | 3(4.5) | 0.667 |
| Seton (%) | 22(34.3) | 29(43.9) | 0.264 |
| Fistulotomy(%) | 20(31.3) | 19(28.8) | 0.544 |
| Seton plus fistulotomy(%) | 15(23.4) | 11(16.7) | 0.335 |
| Rectal advancement flap(%) | 3(4.7) | 2(3) | 0.623 |
| Ligation of the intersphincteric fistula tract(%) | 4(6.3) | 5(7.6) | 0.766 |
| WBC(%) | 7.3(2.97–13.5) | 8.03(3.53–13.4) | 0.5 |
| CRP(%) | 38.75(1–110.4) | 46.36(2.04–222) | 0.481 |
| Combination therapy(%) | 28 | ||
| Perianal fistula relapse(%) | 30(46.9) | 14(21.2) | 0.002 |
Note: Data are presented as n (%) or median (25th–75th percentile).
Abbreviations: PSI, perianal surgical intervention; IFX, infliximab; WBC, white blood cell count; CRP, C‐reactive protein.